Thrombotic thrombocytopenic purpura

Thrombotic thrombocytopenic purpura (TTP or Moschcowitz syndrome^[1]:822) is a rare disorder of the blood-coagulation system, causing extensive microscopic thromboses to form in small blood vessels throughout the body (thrombotic microangiopathy).^[2][3] Most cases of TTP arise from inhibition of the enzyme ADAMTS13, a metalloprotease responsible for cleaving large multimers of von Willebrand factor (vWF) into smaller units. A rarer form of TTP is genetically inherited as dysfunction of ADAMTS13. If large vWF multimers persist there is tendency for increased coagulation. ^[4]

Red blood cells passing the microscopic clots are subjected to shear stress which damages their membranes, leading to intravascular hemolysis and schistocyte formation. Reduced blood flow due to thrombosis and cellular injury results in end organ damage. Current therapy is based on support and plasmapheresis to reduce circulating antibodies against ADAMTS13 and replenish blood levels of the enzyme.^[4]

Signs and symptoms

Classically, the following five features ("pentad") are indicative of TTP;^[5] in most cases, some of these are absent.^[3]

• Fluctuating neurological symptoms, such as bizarre behavior, altered mental status, stroke or headaches
• Kidney failure
• Fever
• Thrombocytopenia (low platelet count), leading to bruising or purpura
• Microangiopathic hemolytic anemia (anemia, jaundice and a characteristic blood film)

A patient may notice dark urine from the hemolytic anemia. Because of the many small areas of ischemia produced by clots in the microvasculature, symptoms may be diffuse and fluctuating, including the classical bruising, confusion, or headache, but also nausea and vomiting (from ischemia in the GI tract or from central nervous system involvement), chest pain from cardiac ischemia, seizures, muscle and joint pain, etc.^{[citation needed]}.

Causes and pathogenesis

TTP, as with other microangiopathic hemolytic anemias (MAHAs), is caused by spontaneous aggregation of platelets and activation of coagulation in the small blood vessels. Platelets are consumed in the coagulation process, and bind fibrin, the end product of the coagulation pathway. These platelet-fibrin complexes form microthrombi which circulate in the vasculature and cause shearing of red blood cells, resulting in hemolysis.^[3]

Roughly, there are two forms of TTP: idiopathic and secondary TTP. A special case is the inherited deficiency of ADAMTS13, known as the Upshaw-Schülman syndrome.^[3]

Idiopathic TTP

The idiopathic form of TTP was recently linked to the inhibition of the enzyme ADAMTS13 by antibodies, rendering TTP an autoimmune disease. ADAMTS13 is a metalloproteinase responsible for the breakdown of von Willebrand factor (vWF), a protein that links platelets, blood clots, and the blood vessel wall in the process of blood coagulation. Very large vWF molecules are more prone to lead to coagulation. Hence, without proper cleavage of vWF by ADAMTS13, coagulation occurs at a higher rate, especially in the part of the blood vessel system where vWF is most active due to high shear stress: in the microvasculature.^[4]

In idiopathic TTP, severely decreased (<5% of normal) ADAMTS13 activity can be detected in most (80%) patients, and inhibitors are often found in this subgroup (44-56%). The relationship of reduced ADAMTS13 to the pathogenesis of TTP is known as the Furlan-Tsai hypothesis, after the two independent groups of researchers who published their research in the same issue of the New England Journal of Medicine in 1998.^[6][7][8] This theory is seen as insufficient to explain the etiology of TTP, since many patients with hereditary lack of ADAMTS13 activity do not manifest clinical symptoms of TTP.^{[citation needed]}

Secondary TTP

Secondary TTP is diagnosed when the patient's history mentions one of the known features associated with TTP. It comprises about 40% of all cases of TTP. Predisposing factors are:^[3]

• Cancer
• Bone marrow transplantation
• Pregnancy
• Medication use:
  • Quinine
  • Platelet aggregation inhibitors (ticlopidine and clopidogrel)
  • Immunosuppressants (cyclosporine, mitomycin, tacrolimus/FK506, interferon-α)
• HIV-1 infection

The mechanism of secondary TTP is poorly understood, as ADAMTS13 activity is generally not as depressed as in idiopathic TTP, and inihibitors cannot be detected. Probable etiology may involve, at least in some cases, endothelial damage.^{[citation needed]}

Upshaw-Schülman syndrome

A hereditary form of TTP is called the Upshaw-Schülman syndrome; this is generally due to inherited deficiency of ADAMTS13 (frameshift and point mutations).^[9][10][11] Patients with this inherited ADAMTS13 deficiency have a surprisingly mild phenotype, but develop TTP in clinical situations with increased von Willebrand factor levels, e.g. infection. Reportedly, 5-10% of all TTP cases are due to Upshaw-Schülman syndrome.^{[citation needed]}

Treatment

Since the early 1990s, plasmapheresis has become the treatment of choice for TTP.^[12] This is an exchange transfusion involving removal of the patient's blood plasma through apheresis and replacement with donor plasma (fresh frozen plasma or cryosupernatant); the procedure has to be repeated daily to eliminate the inhibitor and ablate the symptoms. Lactate dehydrogenase levels are generally used to monitor disease activity. Plasmapheresis may need to be continued for 1–8 weeks before patients with idiopathic TTP cease to consume platelets and begin to normalize their hemoglobin. No single laboratory test (platelet count, LDH, ADAMTS13 level, or inhibitory factor) is indicative of recovery; research protocols have used improvement or normalization of LDH as a measure for ending plasmapheresis. Although patients may be critically ill with failure of multiple organ systems during the acute illness, including renal failure, myocardial ischemia, and neurologic symptoms, recovery over several months may be complete in the absence of a frank myocardial infarct, stroke, or CNS hemorrhage.^{[citation needed]}

Many TTP patients need additional immunosuppressive therapy, with glucocorticoid steroids (e.g. prednisolone or prednisone), vincristine, cyclophosphamide, splenectomy or a combination of the above.

Children with Upshaw-Schulman syndrome receive plasma every two to three weeks prophylactically; this maintains adequate levels of functioning ADAMTS13.

Measuring LDH level, platlets counts and schistocytes under high power fields are used to monitor disease progression or remission.

Epidemiology

The incidence of TTP is about 4-6 per million people per year^[13]. Idiopathic TTP occurs more often in women and black/African-American people, while the secondary forms do not show this distribution.^{[citation needed]} Pregnant women and women in the postpartum period accounted for a notable portion (12-31%) of the cases in some studies; TTP affects approximately 1 in 25,000 pregnancies.^[14]

Prognosis

The mortality rate is approximately 95% for untreated cases, but the prognosis is reasonably favorable (80-90%) for patients with idiopathic TTP diagnosed and treated early with plasmapheresis.^[15]

Approximately one-third of patients experiencing a TTP episode have a relapse within 10 years following their first attack.^{[citation needed]}

Secondary TTP still has a dismal prognosis, with mortality rates despite treatment being reported as 59% to 100%.^{[citation needed]}

History

TTP was initially described by Dr Eli Moschcowitz at the Mount Sinai Hospital in New York City in 1925. Moschcowitz ascribed the disease (incorrectly, as it turned out) to a toxic cause. Moschcowitz noted that his patient, a 16 year-old girl, had anemia; petechiae(purpura); microscopic hematuria; and at autopsy, disseminated microvascular thrombi.^[16] In 1966, a review of 16 new cases and 255 previously reported ones led to the formulation of the classical pentad of symptoms and findings; in this series, mortality rates were found to be very high (90%).^[5] While response to blood transfusion have been noted before, a 1978 report and subsequent studies showed that blood plasma was highly effective in improving the disease process.^[13] In 1991 it was reported that plasma exchange provided better response rates compared to plasma infusion.^[17] In 1982 the disease had been linked with abnormally large von Willebrand factor multimers, and the late 1990s saw the identification of a missing protease activity from people with TTP. ADAMTS13 was identified on a molecular level in 2001.^[13]

References

External links

• Thrombotic thrombocytopenic purpura
• What is TTP?
• Platelets on the Web
• [1] Merck Manual